Sign in
Create a Profile
A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Diseases and Conditions Researched
HIV
What is the purpose of this trial?
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an integrase inhibitor (INI) containing regimenParticipation Guidelines
Age: 18 Years and older
Gender: Both
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | ViiV Healthcare |
|---|---|
| Study HIC#: | 1106008652 |
How will my information be used?
For more information about this trial, contact:
Cyndi Frank
203-785-6939
cyndi.frank@yale.edu
Principal Investigator
Michael J Kozal
Internal Medicine
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
